Dietary Mg intake and biomarkers of inflammation and endothelial dysfunction

Magnesium in Human Health and Disease

Volumn , Issue , 2013, Pages 35-50

  Liu, Simin ^a   Chacko, Sara A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C reactive protein; Diabetes; Dietary magnesium; Endothelial dysfunction; Inflammation

Indexed keywords

EID: 85015590234     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-044-1_2     Document Type: Chapter

References (114)

1. Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. J Nutr. 2003;133(9): 2879-82.
2. Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28(6):1438-44.
3. Song Y, Sesso HD, Manson JE, Cook NR, Buring JE, Liu S. Dietary magnesium intake and risk of incident hyper-tension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol. 2006;98(12):1616-21.
4. Song Y, Manson JE, Buring JE, Liu S. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care. 2004;27(1):59-65.
5. Vormann J. Magnesium: nutrition and metabolism. Mol Aspects Med. 2003;24(1-3):27-37.
6. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta. 2000;294(1-2):1-26.
7. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res. 2010;134(2):119-29. Epub 2009 Jul 24.
8. Wolf FI, Torsello A, Fasanella S, Cittadini A. Cell physiology of magnesium. Mol Aspects Med. 2003;24(1-3):11-26.
9. Arnaud MJ. Update on the assessment of magnesium status. Br J Nutr. 2008;99 Suppl 3:S24-36.
10. Elin RJ. Laboratory tests for the assessment of magnesium status in humans. Magnes Trace Elem. 1991;10(2-4): 172-81.
11. Stipanuk MH. Biochemical and physiological aspects of human nutrition. Philadelphia: W.B. Saunders; 2000.
12. Academy N. Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and flouride. Washington: National Academy Press; 1997.
13. Colditz GA, Manson JE, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and risk of clinical diabetes in women. Am J Clin Nutr. 1992;55(5):1018-23.
14. Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D, Jenkins DJ, et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care. 1997;20(4):545-50.
15. He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation. 2006;113(13):1675-82.
16. Abbott RD, Ando F, Masaki KH, Tung KH, Rodriguez BL, Petrovitch H, et al. Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). Am J Cardiol. 2003;92(6):665-9.
17. Al-Delaimy WK, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Magnesium intake and risk of coronary heart disease among men. J Am Coll Nutr. 2004;23(1):63-70.
18. Ford ES, Li C, McGuire LC, Mokdad AH, Liu S. Intake of dietary magnesium and the prevalence of the metabolic syndrome among U.S. adults. Obesity (Silver Spring). 2007;15(5):1139-46.
19. Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC. Dietaryfiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA. 1997;277(6):472-7.
20. Meyer KA, Kushi LH, Jacobs Jr DR, Slavin J, Sellers TA, Folsom AR. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr. 2000;71(4):921-30.
21. Fung TT, Manson JE, Solomon CG, Liu S, Willett WC, Hu FB. The association between magnesium intake and fasting insulin concentration in healthy middle-aged women. J Am Coll Nutr. 2003;22(6):533-8.
22. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens. 1997;10(3):346-55.
23. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis risk in communities study. J Clin Epidemiol. 1995;48(7):927-40.
24. Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G, Salinas-Martinez AM, Montes-Villarreal J, TrevinoOrtiz JH, et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab. 2004;30(3):253-8.
25. Paolisso G, Sgambato S, Gambardella A, Pizza G, Tesauro P, Varricchio M, et al. Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr. 1992;55(6):1161-7.
26. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med. 2006;23(10):1050-6.
27. Chacko SA, Sul J, Song Y, Li X, LeBlanc J, You Y, Butch A, Liu S. Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. Am J Clin Nutr. 2011;93(2):463-73.
28. Kandeel FR, Balon E, Scott S, Nadler JL. Magnesium deficiency and glucose metabolism in rat adipocytes. Metabolism. 1996;45(7):838-43.
29. Hall S, Keo L, Yu KT, Gould MK. Effect of ionophore A23187 on basal and insulin-stimulated sugar transport by rat soleus muscle. Diabetes. 1982;31(10):846-50.
30. Suarez A, Pulido N, Casla A, Casanova B, Arrieta FJ, Rovira A. Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia. 1995;38(11):1262-70.
31. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19(3):257-67.
32. Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L, et al. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med. 2003;24(1-3):39-52.
33. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys. 2007;458(1):48-56.
34. Abbatecola AM, Ferrucci L, Grella R, Bandinelli S, Bonafe M, Barbieri M, et al. Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc. 2004;52(3):399-404.
35. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102(1):42-7.
36. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-8.
37. Liu S, Tinker L, Song Y, Rifai N, Bonds DE, Cook NR, et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med. 2007;167(15):1676-85.
38. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111-9.
39. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-23.
40. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53(3):693-700.
41. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003;26(6):1745-51.
42. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52(7): 1799-805.
43. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-34.
44. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25(11):2016-21.
45. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-7.
46. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des. 2006;12(13):1623-35.
47. Muir KW, Tyrrell P, Sattar N, Warburton E. Inflammation and ischaemic stroke. Curr Opin Neurol. 2007;20(3):334-42.
48. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-43.
49. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237-42.
50. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
51. Kumar V. Robbins basic pathology, 7th ed updated. Philadelphia: Elsevier Science, 2005.
52. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91.
53. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, Hu FB, et al. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes. 2007;56(7):1898-904.
54. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-7.
55. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-801.
56. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4-7.
57. Ridker PM. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003;108(12):e81-5.
58. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15(8):1983-92.
59. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J. 1994;8(8):504-12.
60. Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol. 1999;19(7):1595-9.
61. Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A, et al. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension. 1999;34(4 Pt 1):568-73.
62. Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998;18(5):723-31.
63. Hackman A, Abe Y, Insull Jr W, Pownall H, Smith L, Dunn K, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93(7):1334-8.
64. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis. 2002;161(1):233-42.
65. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291(16):1978-86.
66. Schram MT, Stehouwer CD. Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome. Horm Metab Res. 2005;37 Suppl 1:49-55.
67. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999;107(1):85-97.
68. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis. 2003;169(2):283-91.
69. Witte DR, Broekmans WM, Kardinaal AF, Klopping-Ketelaars IA, van Poppel G, Bots ML, et al. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis. 2003;170(1):147-53.
70. Galland L. Magnesium and immune function: an overview. Magnesium. 1988;7(5-6):290-9.
71. McCoy H, Kenney MA. Magnesium and immune function: recent findings. Magnes Res. 1992;5(4):281-93.
72. Malpuech-Brugere C, Nowacki W, Daveau M, Gueux E, Linard C, Rock E, et al. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta. 2000;1501(2-3):91-8.
73. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol. 1992;263(3 Pt 2):R734-7.
74. Bussiere FI, Tridon A, Zimowska W, Mazur A, Rayssiguier Y. Increase in complement component C3 is an early response to experimental magnesium deficiency in rats. Life Sci. 2003;73(4):499-507.
75. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol. 2002;40(11):1984-90.
76. Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010;11(5):675-84.
77. Alcock NW, Shils ME, Lieberman PH, Erlandson RA. Thymic changes in the magnesium-depleted rat. Cancer Res. 1973;33(9):2196-204.
78. Malpuech-Brugere C, Nowacki W, Gueux E, Kuryszko J, Rock E, Rayssiguier Y, et al. Accelerated thymus involution in magnesium-deficient rats is related to enhanced apoptosis and sensitivity to oxidative stress. Br J Nutr. 1999;81(5):405-11.
79. Malpuech-Brugere C, Kuryszko J, Nowacki W, Rock E, Rayssiguier Y, Mazur A. Early morphological and immunological alterations in the spleen during magnesium deficiency in the rat. Magnes Res. 1998;11(3):161-9.
80. Nishio A, Ishiguro S, Miyao N. Toxicological and pharmacological studies on magnesium deficiency in rats: histamine-metabolizing enzymes in some tissues of magnesium-deficient rats. Nihon Juigaku Zasshi. 1983;45(6):699-705.
81. Ishiguro S, Nishio A, Miyao N, Morikawa Y, Takeno K, Yanagiya I. Studies on histamine containing cells in the spleen of the magnesium-deficient rats. Nihon Yakurigaku Zasshi. 1987;90(3):141-6.
82. Bernardini D, Nasulewic A, Mazur A, Maier JA. Magnesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Front Biosci. 2005;10:1177-82.
83. Maier JA, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta. 2004;1689(1):13-21.
84. Fullerton DA, Hahn AR, Agrafojo J, Sheridan BC, McIntyre Jr RC. Magnesium is essential in mechanisms of pulmonary vasomotor control. J Surg Res. 1996;63(1):93-7.
85. Altura BM, Gebrewold A, Zhang A, Altura BT. Low extracellular magnesium ions induce lipid peroxidation and activation of nuclear factor-kappa B in canine cerebral vascular smooth muscle: possible relation to traumatic brain injury and strokes. Neurosci Lett. 2003;341(3):189-92.
86. Rayssiguier Y, Gueux E, Bussiere L, Durlach J, Mazur A. Dietary magnesium affects susceptibility of lipoproteins and tissues to peroxidation in rats. J Am Coll Nutr. 1993;12(2):133-7.
87. Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B, et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr. 2006;84(5):1062-9.
88. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr. 2004;80(4):1029-35.
89. Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Stanek 3rd EJ, et al. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr. 2006;83(4):760-6.
90. Ma Y, Hebert JR, Li W, Bertone-Johnson ER, Olendzki B, Pagoto SL, et al. Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. Nutrition. 2008;24(10):941-9.
91. Chacko SA, Song Y, Nathan L, Tinker L, de Boer IH, Tylavsky F, Wallace R, Liu S. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of post-menopausal women. Diabetes Care. 2010;33(2):304-310.
92. Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr. 2007;85(4):1068-74.
93. King DE, Mainous 3rd AG, Geesey ME, Woolson RF. Dietary magnesium and C-reactive protein levels. J Am Coll Nutr. 2005;24(3):166-71.
94. Kim DJ, Xun P, Liu K, Loria C, Yokota K, Jacobs Jr DR, et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care. 2010;33(12):2604-10.
95. de Oliveira Otto MC, Alonso A, Lee DH, Delclos GL, Jenny NS, Jiang R, et al. Dietary micronutrient intakes are associated with markers of inflammation but not with markers of subclinical atherosclerosis. J Nutr. 2011;141(8):1508-15.
96. Rodriguez-Moran M, Guerrero-Romero F. Serum magnesium and C-reactive protein levels. Arch Dis Child. 2008;93(8):676-80.
97. Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord. 2002;26(4): 469-74.
98. Rodriguez-Moran M, Guerrero-Romero F. Elevated concentrations of TNF-alpha are related to low serum magnesium levels in obese subjects. Magnes Res. 2004;17(3):189-96.
99. Almoznino-Sarafian D, Berman S, Mor A, Shteinshnaider M, Gorelik O, Tzur I, et al. Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr. 2007;46(4): 230-7.
100. Nielsen FH, Johnson LK, Zeng H. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep. Magnes Res. 2010;23(4):158-68.
101. Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res. 2010;23(3):131-7.
102. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000;102(19):2353-8.
103. Nielsen FH. Magnesium, inflammation, and obesity in chronic disease. Nutr Rev. 2010;68(6):333-40.
104. Agus MS, Agus ZS. Cardiovascular actions of magnesium. Crit Care Clin. 2001;17(1):175-86.
105. Nielsen FH, Milne DB, Gallagher S, Johnson L, Hoverson B. Moderate magnesium deprivation results in calcium retention and altered potassium and phosphorus excretion by postmenopausal women. Magnes Res. 2007;20(1): 19-31.
106. Malpuech-Brugere C, Rock E, Astier C, Nowacki W, Mazur A, Rayssiguier Y. Exacerbated immune stress response during experimental magnesium deficiency results from abnormal cell calcium homeostasis. Life Sci. 1998;63(20):1815-22.
107. Bussiere FI, Gueux E, Rock E, Mazur A, Rayssiguier Y. Protective effect of calcium deficiency on the inflammatory response in magnesium-deficient rats. Eur J Nutr. 2002;41(5):197-202.
108. Dunn MJ, Walser M. Magnesium depletion in normal man. Metabolism. 1966;15(10):884-95.
109. Shils ME. Experimental human magnesium depletion. Medicine (Baltimore). 1969;48(1):61-85.
110. Classen HG. Magnesium and potassium deprivation and supplementation in animals and man: aspects in view of intestinal absorption. Magnesium. 1984;3(4-6):257-64.
111. Kramer JH, Mak IT, Phillips TM, Weglicki WB. Dietary magnesium intake influences circulating proinflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress. Exp Biol Med (Maywood). 2003;228(6):665-73.
112. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988;107(1):321-31.
113. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med. 2001;1(3):287-96.
114. U.S. Department of Agriculture and U.S. Department of Health and Human Services. 2010 dietary guidelines for Americans. 7th ed. Washington, DC: U.S. Department of Agriculture and U.S. Department of Health and Human Services; 2010.